Brain Malignancy Steering Committee clinical trials planning workshop: report from the Targeted Therapies Working Group

Brian M Alexander; Evanthia Galanis; W K Alfred Yung; Karla V Ballman; James M Boyett; Timothy F Cloughesy; John F Degroot; Jason T Huse; Bhupinder Mann; Warren Mason; Ingo K Mellinghoff; Tom Mikkelsen; Paul S Mischel; Brian P O'Neill; Michael D Prados; Jann N Sarkaria; Abdul Tawab-Amiri; Lorenzo Trippa; Xiaobu Ye; Keith L Ligon; Donald A Berry; Patrick Y Wen

doi:10.1093/neuonc/nou154

Brain Malignancy Steering Committee clinical trials planning workshop: report from the Targeted Therapies Working Group

Neuro Oncol. 2015 Feb;17(2):180-8. doi: 10.1093/neuonc/nou154. Epub 2014 Aug 26.

Authors

Brian M Alexander¹, Evanthia Galanis¹, W K Alfred Yung¹, Karla V Ballman¹, James M Boyett¹, Timothy F Cloughesy¹, John F Degroot¹, Jason T Huse¹, Bhupinder Mann¹, Warren Mason¹, Ingo K Mellinghoff¹, Tom Mikkelsen¹, Paul S Mischel¹, Brian P O'Neill¹, Michael D Prados¹, Jann N Sarkaria¹, Abdul Tawab-Amiri¹, Lorenzo Trippa¹, Xiaobu Ye¹, Keith L Ligon¹, Donald A Berry¹, Patrick Y Wen¹

Affiliation

¹ Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts (B.M.A., L.T., K.L.L., P.Y.W.); Mayo Clinic, Rochester, Minnesota (E.G., K.V.B., B.P.O., J.N.S.); The University of Texas M.D. Anderson Cancer Center, Houston, Texas (W.K.A.Y., J.F.D., D.A.B.); St. Jude Children's Research Hospital, Memphis, Tennessee (J.M.B.); University of California, Los Angeles, California (T.F.C.); Memorial Sloan-Kettering Cancer Center, New York, New York (J.T.H., I.K.M.); National Cancer Institute, Bethesda, Maryland (B.M., A.T.-A.); Princess Margaret Cancer Centre, Toronto, Ontario, Canada (W.M.); Henry Ford Hospital, Detroit, Michigan (T.M.); University of California, San Diego, La Jolla, California (P.S.M.); University of California, San Francisco, California (M.D.P.); Johns Hopkins University, Baltimore, Maryland (X.Y.).

Abstract

Glioblastoma is the most common primary brain malignancy and is associated with poor prognosis despite aggressive local and systemic therapy, which is related to a paucity of viable treatment options in both the newly diagnosed and recurrent settings. Even so, the rapidly increasing number of targeted therapies being evaluated in oncology clinical trials offers hope for the future. Given the broad range of possibilities for future trials, the Brain Malignancy Steering Committee convened a clinical trials planning meeting that was held at the Udvar-Hazy Center in Chantilly, Virginia, on September 19 and 20, 2013. This manuscript reports the deliberations leading up to the event from the Targeted Therapies Working Group and the results of the meeting.

Keywords: adaptive randomization; biomarkers; clinical trials; glioblastoma.

Publication types

Review

MeSH terms

Biomarkers
Brain Neoplasms / diagnosis*
Brain Neoplasms / therapy*
Clinical Trials as Topic*
Endpoint Determination
Glioblastoma / diagnosis*
Glioblastoma / therapy*
Humans

Substances

Biomarkers

Abstract

Publication types

MeSH terms

Substances

Grants and funding